KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $17.5 billion.

  • Royalty Pharma's Non-Current Assets rose 7.69% to $17.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 billion, marking a year-over-year increase of 7.69%. This contributed to the annual value of $16.4 billion for FY2024, which is 8.69% up from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Non-Current Assets is $17.5 billion, which was up 4.14% from $16.8 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Non-Current Assets ranged from a high of $17.5 billion in Q3 2025 and a low of $13.5 billion during Q1 2021.
  • In the last 3 years, Royalty Pharma's Non-Current Assets had a median value of $15.1 billion in 2023 and averaged $15.5 billion.
  • Its Non-Current Assets has fluctuated over the past 5 years, first fell by 7.85% in 2023, then increased by 15.01% in 2024.
  • Quarterly analysis of 5 years shows Royalty Pharma's Non-Current Assets stood at $14.6 billion in 2021, then fell by 2.59% to $14.3 billion in 2022, then increased by 5.96% to $15.1 billion in 2023, then climbed by 8.69% to $16.4 billion in 2024, then increased by 7.69% to $17.5 billion in 2025.
  • Its Non-Current Assets was $17.5 billion in Q3 2025, compared to $16.8 billion in Q2 2025 and $15.8 billion in Q1 2025.